Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
 reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Pages:
  • 1
  • 2
  • 3
  • Rheumatoid Arthritis: KOL Insight [2017]
    Learn More Rheumatoid Arthritis: KOL Insight [2017]
    How are biosimilar anti-TNFs faring? Will your brand be affected? After several years on the US market, the availability of Pfizer’s Xeljanz in the EU is generally welcomed by KOLs; however, it now looks like Eli...
  • Head and Neck Squamous Cell Cancer: KOL Insight [2017]
    Learn More Head and Neck Squamous Cell Cancer: KOL Insight [2017]
    How will immunotherapy continue to shape the HNSCC treatment landscape? The availability of Merck &Co.’s Keytruda and BMS’ Opdivo has already transformed the second-line treatment of head and neck...
  • Cystic Fibrosis: KOL Insight [2017]
    Learn More Cystic Fibrosis: KOL Insight [2017]
    How will the novel CFTR-function restoring therapies impact the CF landscape? The arrival of Vertex’s Kalydeco and Orkambi was a major advance in the disease-modifying CF therapy. However, despite their...
  • Acute Myeloid Leukaemia (AML): KOL Insight [2017]
    Learn More Acute Myeloid Leukaemia (AML): KOL Insight [2017]
    Will novel targeted therapies change AML treatment pathways?  For decades, chemotherapies have been at the forefront of AML treatment. How is this all set to change within the next few years? Novartis’...
  • Targeted Therapies in Asthma: KOL Insight (2017)
    Learn More Targeted Therapies in Asthma: KOL Insight (2017)
    As new targeted asthma therapies emerge, is time running out for Xolair? Xolair’s unique position in the targeted asthma treatment market is under threat. Teva’s Cinqair and GSK’s Nucala have emerged...
  • Rheumatoid Arthritis: Payer Insight 2016
    Learn More Rheumatoid Arthritis: Payer Insight 2016
    Latest Update This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent biosimilar launches in the US such as Pfizer’s Inflectra (infliximab-dyyb) and...
  • Malignant Melanoma: KOL Insight 2016
    Learn More Malignant Melanoma: KOL Insight 2016
    New combinations emerging as immunotherapies become the backbone therapy Immunotherapies have become the go-to treatment for malignant melanoma, and with good reason. Not only are they proving to be the most effective...
  • Multiple Sclerosis: KOL Insight 2016
    Learn More Multiple Sclerosis: KOL Insight 2016
    Latest Update Gain new KOL insights on the latest events happening in multiple sclerosis (MS). Topics covered include; reactions to the latest safety and efficacy data for ibudilast (MediciNova) in progressive MS; the...
  • Ulcerative Colitis: KOL Insight 2016
    Learn More Ulcerative Colitis: KOL Insight 2016
    Latest Update Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on; Protagonist Therapeutics...
  • Colorectal Cancer: KOL Insight 2016
    Learn More Colorectal Cancer: KOL Insight 2016
    KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). Some say novel...
  • Type 2 Diabetes Mellitus: KOL Insight (2016)
    Learn More Type 2 Diabetes Mellitus: KOL Insight (2016)
    Can top-ranked GLP1 agonists move out of the third-line setting? GLP1 agonists may be the top-ranked type 2 diabetes mellitus (T2DM) treatment according to the American Association of Clinical Endocrinologists (AACE),...
  • Prostate Cancer: KOL Insight 2016
    Learn More Prostate Cancer: KOL Insight 2016
    Latest Update Gain new KOL insights on the latest events happening in prostate cancer (PC). In December 2016, Pfizer and Astellas Pharmaceuticals announced the Phase IV PLATO study, evaluating continued treatment with...
  • Chronic Lymphocytic Leukaemia: KOL Insight
    Learn More Chronic Lymphocytic Leukaemia: KOL Insight
    Latest Update Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of chronic lymphocytic leukaemia (CLL). Topics covered include several pieces of...
  • Non Small Cell Lung Cancer (NSCLC): KOL Insight
    Learn More Non Small Cell Lung Cancer (NSCLC): KOL Insight
    Latest Update Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including; the FDA accepting Merck and Co.’s regulatory filing for Keytruda (pembrolizumab) in combination...
  • Multiple Sclerosis: Payer Insight
    Learn More Multiple Sclerosis: Payer Insight
    Drug prices rising while needs remain unmet. Now payers are fighting back Payers have had it with the high cost of Multiple Sclerosis (MS) drugs and now they’re fighting back—demanding better data to justify...
  • Psoriasis: KOL Insight
    Learn More Psoriasis: KOL Insight
      Latest Update: Positive results for Phase III CIMPASI and CIMPACT programmes Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of moderate to severe plaque...
  • Age-Related Macular Degeneration (AMD): KOL Insight
    Learn More Age-Related Macular Degeneration (AMD): KOL Insight
    Innovation on all fronts as drug-makers and doctors reimagine wAMD treatment Find out how next-generation VEGF inhibitors and other pipeline drugs will transform wet age-related macular degeneration (wAMD) treatment...
  • Idiopathic Pulmonary Fibrosis (IPF): KOL Insight
    Learn More Idiopathic Pulmonary Fibrosis (IPF): KOL Insight
    What’s on the KOL ‘wish list’ for the next generation of IPF treatments? Physicians currently only have two options for Idiopathic Pulmonary Fibrosis (IPF) sufferers: how do they decide between them?...
  • Multiple Myeloma: KOL Insight
    Learn More Multiple Myeloma: KOL Insight
    Latest Update This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; Amgen’s announcement of positive results from a planned...
  • Nonalcoholic Steatohepatitis (NASH): KOL Insight
    Learn More Nonalcoholic Steatohepatitis (NASH): KOL Insight
    Who will benefit most from huge opportunities in NASH treatment? The first new NASH therapy is due soon: but is it safe and effective enough? How happy are KOLs with the plethora of current trials and endpoints? Which...
  • Pages:
  • 1
  • 2
  • 3

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved